that was reportedly also involved in negotiations to buy out the company. If approved, it would become a companion to Merck's Bayer-partnered heart failure drug Verquvo (vericiguat), cleared by ...

Rather, it brings with it platform capabilities in formulations of mRNA drugs ... disease applications including heart failure. "The acquisition of Exelead will further enable Merck to capture ...

Merck buys rights to heart disease drug in latest China deal Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion ...

With a market cap of $102.2 billion, the company focuses on products and experimental therapies address cancer, heart disease ... to strong growth in key drugs like Opdivo, Breyanzi, Reblozyl ...

"We have huge manufacturing capacity right now ... Even the drugs that outperformed Wall Street expectations in the first quarter face headwinds. Sales of its heart disease drug, sold under ...

Most staff are in place and drug reviews are moving forward ... 40% of Americans living with diseases like hypertension and heart disease and driving more than $4.5 trillion in annual healthcare ...

Some scientific research supports the use of rhodiola for stress reduction, which may also help reduce the risk of heart disease, depression ... disorder when combined with Zoloft (sertraline), a ...

For example, damage to the right side of the brain typically causes ... Know stroke. National Heart, Lung, and Blood Institute. Stroke—treatment. Centers for Disease Control and Prevention. Low blood ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.